Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04
Details : LEVI-04 is a novel neurotrophin-modulating biological agent. It is under phase 2 clinical development for the treatment of chronic pain in patients with osteoarthritis.
Product Name : LEVI-04
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 498-02-2
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APPA, is a patented, combination oral therapy of two synthetically produced isomers, an investigational NFkB and Nrf2 modulator, essential for maintaining coordinated cellular responses to resolve the inflammatory status of the cell/tissue.
Product Name : APPA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : CAS 498-02-2
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 498-02-2
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from one study, conducted by Nordic Biosciences found that APPA, an NRf2 and NFkB regulator, reduces inflammation-derived tissue turnover in human cartilage explants and inhibits RANKL-mediated osteoclastogenesis and bone resorption by human oste...
Product Name : APPA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : CAS 498-02-2
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAS 498-02-2,Paeonol
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from the study, conducted by Instituto de Investigación Biomedica da Coruña, Spain, found that APPA, an NRf2 and NFkB regulator, has a clear anti-inflammatory effect on human articular chondrocytes, and could reduce extracellular matrix degrada...
Product Name : APPA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : CAS 498-02-2,Paeonol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable